[go: up one dir, main page]

UY26782A1 - Derivados del benzotiazol - Google Patents

Derivados del benzotiazol

Info

Publication number
UY26782A1
UY26782A1 UY26782A UY26782A UY26782A1 UY 26782 A1 UY26782 A1 UY 26782A1 UY 26782 A UY26782 A UY 26782A UY 26782 A UY26782 A UY 26782A UY 26782 A1 UY26782 A1 UY 26782A1
Authority
UY
Uruguay
Prior art keywords
benzotiazole
derivatives
compounds
treatment
pharmaceutically acceptable
Prior art date
Application number
UY26782A
Other languages
English (en)
Inventor
Alexander Alanine
Aubry Kern Miller
Alexander Flohr
Claus Riemer
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26782A1 publication Critical patent/UY26782A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invenciĆ³n se refiere a compuestos de la fĆ³rmula general I. Y a las sales farmacĆ©uticamente aceptables para el tratamiento de enfermedades relacionadas con el receptor de adenosina.
UY26782A 2000-06-21 2001-06-20 Derivados del benzotiazol UY26782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113219 2000-06-21

Publications (1)

Publication Number Publication Date
UY26782A1 true UY26782A1 (es) 2001-12-28

Family

ID=8169041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26782A UY26782A1 (es) 2000-06-21 2001-06-20 Derivados del benzotiazol

Country Status (33)

Country Link
US (8) US6521754B2 (es)
EP (2) EP1797878A3 (es)
JP (1) JP3886897B2 (es)
KR (2) KR100526487B1 (es)
CN (1) CN1234358C (es)
AR (1) AR031244A1 (es)
AT (1) ATE385794T1 (es)
AU (2) AU2001281817B2 (es)
BR (1) BR0112395A (es)
CA (1) CA2413086C (es)
CY (1) CY1107401T1 (es)
CZ (1) CZ2003182A3 (es)
DE (1) DE60132777T2 (es)
DK (1) DK1303272T3 (es)
EC (1) ECSP024399A (es)
ES (1) ES2299504T3 (es)
HR (1) HRP20020962A2 (es)
HU (1) HUP0301315A3 (es)
IL (2) IL153278A0 (es)
JO (1) JO2503B1 (es)
MX (1) MXPA02012596A (es)
MY (1) MY138352A (es)
NO (2) NO324635B1 (es)
NZ (1) NZ522928A (es)
PE (1) PE20020104A1 (es)
PL (1) PL207384B1 (es)
PT (1) PT1303272E (es)
RU (1) RU2251419C2 (es)
SI (1) SI1303272T1 (es)
UY (1) UY26782A1 (es)
WO (1) WO2001097786A2 (es)
YU (1) YU96502A (es)
ZA (1) ZA200209730B (es)

Families Citing this family (73)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234358C (zh) * 2000-06-21 2006-01-04 弗Ā·å“ˆå¤«ę›¼-ꋉē½—åˆ‡ęœ‰é™å…¬åø č‹Æå¹¶å™»å”‘č”ē”Ÿē‰©
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
WO2003045385A1 (en) * 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
KR100581703B1 (ko) * 2001-12-12 2006-05-22 ģ—ķ”„. ķ˜øķ”„ė§Œ-ė¼ ė”œģŠˆ ģ•„ź²Œ ģ•„ė°ė…øģ‹  ģˆ˜ģš©ģ²“ ģ”°ģ ˆģ œė”œģ„œģ˜ ė²¤ģ”°ķ‹°ģ˜¤ķŽœ
US20040198753A1 (en) 2002-01-28 2004-10-07 Hiroshi Kase Methods of treating patients suffering from movement disorders
TW200410688A (en) * 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
MXPA05005379A (es) 2002-11-19 2006-02-17 Achillion Pharmaceuticals Inc Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral.
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
KR100699615B1 (ko) 2003-01-13 2007-03-23 ģ—ķ”„. ķ˜øķ”„ė§Œ-ė¼ ė”œģŠˆ ģ•„ź²Œ ė²¤ģ”±ģ‚¬ģ”ø ģœ ė„ģ²“ ė° ģ•„ė°ė…øģ‹  ģˆ˜ģš©ģ²“ ė¦¬ź°„ė“œė”œģ„œģ˜ ģ“ė“¤ģ˜ģš©ė„
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
RU2340612C2 (ru) * 2003-05-13 2008-12-10 Š¤.Š„Š¾Ń„Ń„Š¼Š°Š½Š½-Š›Ń Š Š¾Ńˆ ŠŠ³ 2-ŠøŠ¼ŠøŠ“Š°Š·Š¾Š±ŠµŠ½Š·Š¾Ń‚ŠøŠ°Š·Š¾Š»Ń‹ ŠŗŠ°Šŗ Š»ŠøŠ³Š°Š½Š“ы Š°Š“ŠµŠ½Š¾Š·ŠøŠ½Š¾Š²Š¾Š³Š¾ рŠµŃ†ŠµŠæтŠ¾Ń€Š°
AU2004251814B2 (en) * 2003-05-19 2009-07-23 F. Hoffmann-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
ES2280964T3 (es) 2003-05-21 2007-09-16 F. Hoffmann-La Roche Ag Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.
DK1633355T3 (da) * 2003-05-30 2008-08-04 Hoffmann La Roche Benzothiazol-derivater og anvendelse deraf i behandlingen af sygdomme der er relateret til adenosin A2A-receptoren
DE602004012858T2 (de) * 2003-06-20 2009-05-14 F. Hoffmann-La Roche Ag 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
EA010017B1 (ru) * 2003-07-10 2008-06-30 ŠŃ‡ŠøŠ»Š»ŠøŠ¾Š½ Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š·, Š˜Š½Šŗ. Š—Š°Š¼ŠµŃ‰Ń‘Š½Š½Ń‹Šµ Š°Ń€ŠøŠ»Ń‚ŠøŠ¾Š¼Š¾Ń‡ŠµŠ²ŠøŠ½Ń‹, ŠæрŠøŠ¼ŠµŠ½ŠøŠ¼Ń‹Šµ Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ ŠøŠ½Š³ŠøŠ±ŠøтŠ¾Ń€Š¾Š² рŠµŠæŠ»ŠøŠŗŠ°Ń†ŠøŠø Š²ŠøрусŠ¾Š²
DE602004021206D1 (de) * 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
NZ619746A (en) 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
RU2006112847A (ru) 2003-09-19 2007-11-10 Š¤. Š„Š¾Ń„Ń„Š¼Š°Š½Š½-Š›Ń Š Š¾Ńˆ ŠŠ³ (Ch) ŠŸŃ€Š¾ŠøŠ·Š²Š¾Š“Š½Ń‹Šµ тŠøŠ°Š·Š¾Š»Š¾ŠæŠøрŠøŠ“ŠøŠ½Š° Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ Š»ŠøŠ³Š°Š½Š“Š¾Š² Š°Š“ŠµŠ½Š¾Š·ŠøŠ½Š¾Š²Š¾Š³Š¾ рŠµŃ†ŠµŠæтŠ¾Ń€Š°
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1753760B1 (en) * 2004-05-24 2008-01-02 F.Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
KR100834179B1 (ko) * 2004-05-24 2008-05-30 ģ—ķ”„. ķ˜øķ”„ė§Œ-ė¼ ė”œģŠˆ ģ•„ź²Œ 4-ķ•˜ģ“ė“œė”ģ‹œ-4-ė©”ķ‹ø-ķ”¼ķŽ˜ė¦¬ė”˜-1-ģ¹“ė³µģ‹¤ģ‚°(4-ė©”ķ†”ģ‹œ-7-ėŖØķ“ė¦°-4-ģ¼-ė²¤ģ”°ķ‹°ģ•„ģ”ø-2-ģ¼)-ģ•„ė§ˆģ“ė“œ
EP1773795A1 (en) * 2004-07-22 2007-04-18 F.Hoffmann-La Roche Ag Substituted benzothiazoles
CN1989139B (zh) * 2004-07-22 2010-05-12 弗Ā·å“ˆå¤«ę›¼-ꋉē½—åˆ‡ęœ‰é™å…¬åø č‹Æå¹¶å™»å”‘č”ē”Ÿē‰©
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
CN101056857B (zh) 2004-11-05 2010-12-01 弗Ā·å“ˆå¤«ę›¼-ꋉē½—åˆ‡ęœ‰é™å…¬åø 异ēƒŸé…øč”ē”Ÿē‰©ēš„åˆ¶å¤‡ę–¹ę³•
KR100973609B1 (ko) 2005-03-23 2010-08-03 ģ—ķ”„. ķ˜øķ”„ė§Œ-ė¼ ė”œģŠˆ ģ•„ź²Œ ļ½ļ¼§ļ½Œļ½•ļ¼²2 źøøķ•­ģ œė”œģ„œ ģ•„ģ„øķ‹øė Œģ¼-ķ”¼ė¼ģ”øė”œ-ķ”¼ė¦¬ėÆøė”˜ģœ ė„ģ²“
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US8148536B2 (en) 2006-04-21 2012-04-03 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
US7429589B2 (en) 2006-04-27 2008-09-30 Hoffmann-La Roche Inc. Mono-nitration of aromatic compounds via nitrate salts
WO2007134958A1 (en) * 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
CN101652375B (zh) * 2007-02-14 2016-08-24 å·“ę–Æå¤«ę¬§ę“²å…¬åø ē”µč‡“发光金属ē»œåˆē‰©
ES2571533T3 (es) * 2007-04-27 2016-05-25 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
WO2009015236A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
US7913765B2 (en) * 2007-10-19 2011-03-29 Baker Hughes Incorporated Water absorbing or dissolving materials used as an in-flow control device and method of use
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Ł…Ų“ŲŖŁ‚Ų§ŲŖ ŲØŁ†Ų²ŁˆŲ«ŁŠŲ§Ų²ŁˆŁ„ ŁƒŲ¹ŁˆŲ§Ł…Ł„ Ł…Ų¶Ų§ŲÆŲ© Ł„Ł„Ų³Ų±Ų·Ų§Ł†
KR101064258B1 (ko) 2008-12-29 2011-09-14 ķ•œźµ­ź³¼ķ•™źø°ģˆ ģ—°źµ¬ģ› ė²¤ģ”°ģ•„ė¦“ģš°ė ˆģ“ė„ ķ™”ķ•©ė¬¼, ė° ģ“ė„¼ ķ•Øģœ ķ•˜ėŠ” ķ‡“ķ–‰ģ„± ė‡Œģ§ˆķ™˜ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
RU2455293C2 (ru) * 2010-09-15 2012-07-10 Š“Š¾ŃŃƒŠ“Š°Ń€ŃŃ‚Š²ŠµŠ½Š½Š¾Šµ Š¾Š±Ń€Š°Š·Š¾Š²Š°Ń‚ŠµŠ»ŃŒŠ½Š¾Šµ учрŠµŠ¶Š“ŠµŠ½ŠøŠµ Š²Ń‹ŃŃˆŠµŠ³Š¾ ŠæрŠ¾Ń„ŠµŃŃŠøŠ¾Š½Š°Š»ŃŒŠ½Š¾Š³Š¾ Š¾Š±Ń€Š°Š·Š¾Š²Š°Š½Šøя "ŠŸŠµŃ€Š¼ŃŠŗŠ°Ń Š³Š¾ŃŃƒŠ“Š°Ń€ŃŃ‚Š²ŠµŠ½Š½Š°Ń фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠ°Ń Š°ŠŗŠ°Š“ŠµŠ¼Šøя Š¤ŠµŠ“ŠµŃ€Š°Š»ŃŒŠ½Š¾Š³Š¾ Š°Š³ŠµŠ½Ń‚стŠ²Š° ŠæŠ¾ Š·Š“рŠ°Š²Š¾Š¾Ń…Ń€Š°Š½ŠµŠ½Šøю Šø сŠ¾Ń†ŠøŠ°Š»ŃŒŠ½Š¾Š¼Ńƒ рŠ°Š·Š²ŠøтŠøю" (Š“ŠžŠ£ Š’ŠŸŠž ŠŸŠ“Š¤Š Š Š¾ŃŠ·Š“рŠ°Š²Š°) N-(2-Š±ŠµŠ½Š·Š¾Ń‚ŠøŠ°Š·Š¾Š»ŠøŠ»)Š°Š¼ŠøŠ“ 3-Š±Ń€Š¾Š¼-2,4-Š“ŠøŠ¾ŠŗсŠ¾-4-(4-Š¼ŠµŃ‚Š¾ŠŗсŠøфŠµŠ½ŠøŠ»)Š±ŃƒŃ‚Š°Š½Š¾Š²Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹, Š¾Š±Š»Š°Š“Š°ŃŽŃ‰ŠøŠ¹ Š³ŠøŠæŠ¾Š³Š»ŠøŠŗŠµŠ¼ŠøчŠµŃŠŗŠ¾Š¹ Š°ŠŗтŠøŠ²Š½Š¾ŃŃ‚ŃŒŃŽ
RU2448100C1 (ru) * 2010-09-24 2012-04-20 Š¢Š°Ń‚ŃŒŃŠ½Š° ŠŠøŠŗŠ¾Š»Š°ŠµŠ²Š½Š° Š˜Š²Š°Š½Š¾Š²Š° ŠŸŃ€Š¾ŠøŠ·Š²Š¾Š“Š½Ń‹Šµ 2-Š°Š¼ŠøŠ½Š¾Š±ŠµŠ½Š·Š¾Ń‚ŠøŠ°Š·Š¾Š»Š°, Š¾Š±Š»Š°Š“Š°ŃŽŃ‰ŠøŠµ ŠæрŠ¾Ń‚ŠøŠ²Š¾Š³ŠøŠæŠ¾ŠŗсŠøчŠµŃŠŗŠ¾Š¹ Š°ŠŗтŠøŠ²Š½Š¾ŃŃ‚ŃŒŃŽ, Šø сŠæŠ¾ŃŠ¾Š± Šøх ŠøсŠæŠ¾Š»ŃŒŠ·Š¾Š²Š°Š½Šøя
WO2012054367A1 (en) * 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
TWI571466B (zh) * 2011-10-14 2017-02-21 č‰¾ä¼Æē¶­ęœ‰é™å…¬åø ē”Øę–¼ę²»ē™‚ē™Œē—‡åŠå…ē–«čˆ‡č‡Ŗ體免ē–«ē–¾ē—…之ē“°čƒžå‡‹äŗ”čŖ˜ē™¼åŠ‘
CN103772376B (zh) * 2012-10-24 2017-01-11 äø­å›½åŒ»å­¦ē§‘学院医čÆē”Ÿē‰©ęŠ€ęœÆē ”ē©¶ę‰€ 取代ēš„č‹Æ并-1,3-ę‚å”‘ē±»åŒ–合ē‰©ć€å…¶åˆ¶å¤‡ę–¹ę³•åŠē”Ø途
ES2886641T3 (es) 2014-08-11 2021-12-20 Angion Biomedica Corp Inhibidores de citocromo P450 y sus usos
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
US11597708B2 (en) 2016-09-16 2023-03-07 Hsf Pharmaceuticals Sa Inhibitors of heat shock factors and uses thereof
EP3661941B1 (en) * 2017-08-01 2022-12-14 Merck Patent GmbH Thiazolopyridine derivatives as adenosine receptor antagonists
EP3686199B9 (en) * 2017-09-28 2022-12-07 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as a2a receptor inhibitor
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
KR102796857B1 (ko) * 2019-10-08 2025-04-15 ķ˜„ėŒ€ģžė™ģ°Øģ£¼ģ‹ķšŒģ‚¬ ėƒ‰ź°ģž„ģ¹˜ģ™€ ėƒ‰ź°ģ‹œģŠ¤ķ…œ ė° ėƒ‰ź°ģ‹œģŠ¤ķ…œģ˜ ģ œģ–“ė°©ė²•
US20230105935A1 (en) * 2019-12-16 2023-04-06 The University Of British Columbia Antiviral compounds, compositions and methods of use
WO2021247921A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Benzothiazole compounds and uses thereof
AU2022214582C1 (en) * 2021-01-29 2025-02-27 Korea Research Institute Of Chemical Technology Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as active ingredient

Family Cites Families (37)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag SchƤdlingsbekƤmpfungsmittel
GB1318291A (en) * 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
LU63457A1 (es) * 1970-07-06 1971-11-12
JPS5516147B2 (es) * 1971-12-24 1980-04-30
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) * 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
US4471957A (en) * 1979-12-03 1984-09-18 Baltimore Therapeutic Equipment Company Method and apparatus for rehabilitation of damaged limbs
CA1153867A (en) 1980-05-16 1983-09-20 Michael A. M. Boersma Process for the preparation of crystalline silicates, crystalline silicates so prepared and process for carrying out catalytic reactions
KR930005004B1 (ko) * 1985-04-15 1993-06-11 ģŸˆģ•ˆģ„¼ ķŒŒģ•„ė§ˆģŠˆģš°ķ‹°ģ¹“ ģ—”. ė¶€ģ“. ģ¹˜ķ™˜ėœ n-[(4-ķ”¼ķŽ˜ė¦¬ė””ė‹)ģ•Œķ‚¬]ģ“ķ™˜ ģ¶•ķ•© ģ˜„ģ‚¬ģ”øģ•„ėƼ ė° ķ‹°ģ•„ģ”øģ•„ėƼģ˜ ģ œģ”°ė°©ė²•
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd AnalogiamenetelmƤ antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5348519A (en) * 1988-02-04 1994-09-20 Loredan Biomedical, Inc. Exercise and diagnostic apparatus and method
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) 1989-05-11 1994-08-31 ę±ę“‹ē“”ēø¾ę Ŗ式会ē¤¾ ę–°č¦ćŖćƒ™ćƒ³ć‚¾ćƒć‚¢ć‚¾ćƒ¼ćƒ«čŖ˜å°Žä½“
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
EP0427963B1 (de) 1989-11-10 1994-03-30 Agrolinz Agrarchemikalien Gesellschaft M.B.H. Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe
US5142910A (en) * 1990-06-27 1992-09-01 Occupational Orthopaedic Systems, Inc. Dynamic physiological function testing apparatus and method
DK0553130T3 (da) * 1990-10-15 1996-02-05 Pfizer Pyrrolidindionderivater
US5275045A (en) * 1991-03-07 1994-01-04 Isotechnologies, Inc. Apparatus and method for use in assessing the lifting capability of a human subject
MX9202022A (es) * 1991-05-01 1992-11-01 Otsuka Pharma Co Ltd Derivados de pirazina y proceso para su preparacion.
DE69327572T2 (de) * 1992-05-21 2000-06-21 Otsuka Pharmaceutical Factory, Inc. PhosphonsƤurediester-derivat
US5312107A (en) * 1993-05-13 1994-05-17 Kordun, Ltd. Golf club swing training and exercise device
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ćƒ”ćƒšćƒ©ć‚øćƒ³čŖ˜å°Žä½“
JPH0940646A (ja) * 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ćƒ™ćƒ³ć‚¼ćƒ³ēø®åˆē’°čŖ˜å°Žä½“又ćÆćć®å”©
FR2753970B1 (fr) * 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ćƒ™ćƒ³ć‚¾ćƒć‚¢ć‚¾ćƒ¼ćƒ«čŖ˜å°Žä½“
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
AU1924099A (en) * 1997-12-18 1999-07-05 Lyonnaise Industrielle Pharmaceutique (Lipha) Piperazine derivatives useful as hypoglycemic agents
EP1049682A1 (en) * 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
CA2345944A1 (en) 1998-09-30 2000-04-06 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
UA71587C2 (uk) * 1998-11-10 2004-12-15 ŠØŠµŃ€Ń–Š½Š³ ŠŠŗцієŠ½Š³ŠµŠ·ŠµŠ»Š»ŃŒŃˆŠ°Ń„Ń‚ ŠŠ¼Ń–Š“Šø Š°Š½Ń‚Ń€Š°Š½Ń–Š»Š¾Š²Š¾Ń— ŠŗŠøсŠ»Š¾Ń‚Šø тŠ° їхŠ½Ń” Š·Š°ŃŃ‚Š¾ŃŃƒŠ²Š°Š½Š½Ń яŠŗ Š»Ń–ŠŗŠ°Ń€ŃŃŒŠŗŠøх Š·Š°ŃŠ¾Š±Ń–Š²
ATE240316T1 (de) * 1998-12-23 2003-05-15 Lilly Co Eli Heteroaromatische amide als inhibitoren von faktor xa
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
CN1234358C (zh) * 2000-06-21 2006-01-04 弗Ā·å“ˆå¤«ę›¼-ꋉē½—åˆ‡ęœ‰é™å…¬åø č‹Æå¹¶å™»å”‘č”ē”Ÿē‰©
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
HK1058148A1 (en) 2004-05-07
BR0112395A (pt) 2003-07-08
US7317007B2 (en) 2008-01-08
DK1303272T3 (da) 2008-05-26
US20050026906A1 (en) 2005-02-03
KR100571161B1 (ko) 2006-04-17
CZ2003182A3 (cs) 2003-06-18
US20080125419A1 (en) 2008-05-29
CN1437471A (zh) 2003-08-20
DE60132777T2 (de) 2009-02-12
NO324635B1 (no) 2007-11-26
MXPA02012596A (es) 2003-04-10
NZ522928A (en) 2005-05-27
US20060003986A1 (en) 2006-01-05
NO20073465L (no) 2002-12-12
KR20030019446A (ko) 2003-03-06
MY138352A (en) 2009-05-29
HRP20020962A2 (en) 2005-02-28
NO20025978D0 (no) 2002-12-12
CY1107401T1 (el) 2012-12-19
AU8181701A (en) 2002-01-02
ES2299504T3 (es) 2008-06-01
IL153278A0 (en) 2003-07-06
HUP0301315A2 (hu) 2003-08-28
US20020045615A1 (en) 2002-04-18
US20080108809A1 (en) 2008-05-08
ZA200209730B (en) 2004-03-01
ATE385794T1 (de) 2008-03-15
US6963000B2 (en) 2005-11-08
WO2001097786A2 (en) 2001-12-27
US20100075959A1 (en) 2010-03-25
HUP0301315A3 (en) 2007-10-29
AR031244A1 (es) 2003-09-17
IL153278A (en) 2012-12-31
EP1303272A2 (en) 2003-04-23
JP2003535887A (ja) 2003-12-02
CA2413086C (en) 2011-06-28
JP3886897B2 (ja) 2007-02-28
WO2001097786A3 (en) 2002-12-12
US6835732B2 (en) 2004-12-28
KR20050043912A (ko) 2005-05-11
AU2001281817B2 (en) 2005-11-24
CA2413086A1 (en) 2001-12-27
PT1303272E (pt) 2008-04-14
DE60132777D1 (de) 2008-03-27
CN1234358C (zh) 2006-01-04
US20030176695A1 (en) 2003-09-18
EP1797878A2 (en) 2007-06-20
ECSP024399A (es) 2003-02-06
YU96502A (sh) 2006-01-16
JO2503B1 (en) 2009-10-05
KR100526487B1 (ko) 2005-11-08
PE20020104A1 (es) 2002-02-16
RU2251419C2 (ru) 2005-05-10
NO20025978L (no) 2002-12-12
US6521754B2 (en) 2003-02-18
PL360697A1 (en) 2004-09-20
PL207384B1 (pl) 2010-12-31
EP1303272B1 (en) 2008-02-13
US20030125318A1 (en) 2003-07-03
SI1303272T1 (sl) 2008-06-30
EP1797878A3 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
UY26782A1 (es) Derivados del benzotiazol
PA8544901A1 (es) Derivados de oxazol
UY26872A1 (es) Derivados de la 4- fenil piridina
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparaciĆ³n y su uso como medicamentos.
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
ES2161290T3 (es) Derivados de quinazolina.
UY26839A1 (es) Productos de derivados de la 4 - fenil - piridina
PA8507601A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
TR200201505T2 (tr) Terapƶtik maddeler olarak pirazolopirimidinler
CR6881A (es) Derivados de pirazol
PA8547701A1 (es) Nucleosidos 4 substituidos.
CR9954A (es) Derivados de pirazina
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
HN2008001666A (es) Derivados acidos de cicloalquilamino
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores
UY27034A1 (es) Derivados de pirimidina
UY27074A1 (es) Derivados de aminotriazolopiridina
DOP2006000287A (es) Derivados de piperidina
PA8531601A1 (es) Nuevos heteroaromatos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140129